Summary & Overview
HCPCS Level II J9072: Injection, cyclophosphamide (Frindovyx), 5 mg
HCPCS Level II code J9072 identifies a 5 mg unit of cyclophosphamide (brand name Frindovyx) used in chemotherapy or immunosuppressive regimens. Nationally, accurate coding for single-unit drug J-codes is critical for billing, utilization tracking, and formulary management, particularly for oncology and infusion services where per-unit billing drives claim amounts and clinical documentation.
Key payers addressed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of what J9072 represents clinically and operationally, plus guidance on typical sites of service and the service type associated with parenteral chemotherapy administration. The publication outlines benchmarks for unit-based drug billing, summarizes relevant policy considerations that commonly affect chemotherapy J-codes (such as medical necessity determination and site-of-service payment differentials), and provides clinical context about cyclophosphamide use in oncology and immunosuppression.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, related codes, and specific payer policy language are noted where applicable.
Billing Code Overview
HCPCS Level II code J9072 represents an injection of cyclophosphamide (Frindovyx), 5 mg. This code denotes a chemotherapy or immunosuppressive drug administration billed for the specified unit of cyclophosphamide.
-
Service type: Drug administration (intravenous or other parenteral injection of a chemotherapeutic/immunosuppressive agent)
-
Typical site of service: Hospital outpatient departments, oncology infusion centers, physician offices, and outpatient clinics where parenteral chemotherapy is administered.
Data not available in the input for associated taxonomies, ICD-10 diagnoses, related codes, and service line.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with a hematologic malignancy such as non-Hodgkin lymphoma or a solid-organ transplant recipient requiring immunosuppression, prescribed intravenous cyclophosphamide (J9072, 5 mg unit) as part of an oncology or immunosuppressive regimen. The clinical workflow begins with oncology or transplant clinic evaluation, review of recent labs (CBC, renal and hepatic panels), and confirmation of treatment intent. The patient presents to an outpatient infusion center or hospital infusion suite where an oncology RN verifies identity, performs pre-infusion assessment, and establishes IV access. Pre-medications (antiemetic or mesna for uroprotection if indicated) are administered per protocol. The pharmacy compounds the appropriate cyclophosphamide dose using J9072 billing units and delivers the product to the infusion area with documentation of lot number and expiration. During infusion, nursing monitors vital signs, infusion site, and for acute adverse reactions; post-infusion monitoring includes assessment for nausea, cytopenias, hemorrhagic cystitis risk and instruction on infection precautions. Documentation includes diagnosis linking, dose calculation, lot/JW/JZ reporting as required, and any applicable modifiers for medical necessity, drug wastage, or technical circumstances.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW |